
News Release

For Immediate Release

01 July 2013

Contact: **Tricia Thompson**
Business Development
+1 (610) 539-3670

Ground-breaking PluroGel® Clinical Results Symposium Conducted During European Wound Management Association (EWMA) Conference 2013 15 to 17 May, Copenhagen, Denmark

(Norristown, Pennsylvania, USA, 01 July 2013) - PluroGen Therapeutics, Inc., a leader in advanced wound care solutions, announced today that a ground-breaking Symposium on its PluroGel® Products was conducted during the 2013 European Wound Management Association (EWMA) Conference in Copenhagen, Denmark, 15-17 May.

The 2013 Symposium included presentations covering clinical successes and cost savings from 10 centers in 7 countries reporting results from a population of over 1,200 patients. The 2013 PluroGel® Symposium was well attended, the symposium room being filled at capacity with over 70 invited doctors and nurses in the audience to hear and ask questions on the clinical advantages and cost savings achieved by the use of PluroGel® Products. The 2013 Symposium significantly expanded on the patient successes and unique PluroGel® benefits reported at the 2012 PluroGel® Products Symposium. Presentations from the 2013 Symposium can be viewed at our website, www.plurogen.com, with a password supplied by PluroGen. To obtain a password, please contact PluroGen at info@plurogen.com.

"We continued to tell our story about how our new PluroGel® surfactant products are helping physicians make great strides in their day to day wound care challenges" commented Neal Koller, President and CEO of PluroGen. "The results are consistent and exemplify how PluroGel® Products can create much-improved opportunities for wound care management. It's wonderful to be able to have such a positive impact for doctors, nurses and, most importantly, patients."

About PluroGen Therapeutics, Inc.

PluroGen Therapeutics, Inc. is a burn, wound, and skin care company providing clinically advanced and superior products from its multiple, patent-protected technology platforms. The Company's primary platform is its core PluroGel® surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products. Products based on PluroGel® are University developed and are in routine use, having shown superior results on more than 12,000 patients in two different patient populations- severe burns and non-healing wounds. PluroGen's three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration. PluroGen has a strong new product pipeline and its senior management, operations team, boards and principal investigators are all recognized global, commercial and clinical leaders in PluroGen's target markets of burn and wound care.

More information can be found on the company web site at www.plurogen.com. For PluroGen Investor Information please call +1 (610) 539-3670.

About European Wound Management Association

The European Wound Management Association (EWMA) was founded in 1991, and the association works to promote the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all etiologies.

Safe Harbor Statement:

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.